Summary We reviewed 319 primary breast tumours for cytosolic pS2 content, with a median follow-up of 6 years. pS2 status correlated positively with oestradiol and progesterone receptors and negatively with Scarff, Bloom and Richardson grade. pS2 positivity was associated with longer overall survival, particularly in patients who received hormone therapy, in whom pS2 status was also predictive of the response to therapy.
Proliferation of human breast cancer can be oestradiol dependent. In such cases hormonal therapy provides an objective benefit. The failure of 30-40% of patients with oestradiol receptor (ER)-rich tumours to respond to endocrine therapy was ascribed to either tumour heterogeneity or absence of progesterone receptor (PR) (McGuire et al., 1978; Jensen et al., 1982) . Determination of PR content improves the diagnosis of hormone dependence (Horwitz et al., 1975) , but about 20% of ER-positive, PR-positive tumours do not respond to hormone therapy. There is thus a need for other markers of hormone responsiveness.
The pS2 gene has been cloned in the breast cancer cell line MCF7 cDNA library (Masiakovski et al., 1982) , and its expression is oestradiol regulated at the transcriptional level through the ER pathway (Berry et al., 1989) . Both pS2 mRNA and protein have been observed in human breast tumours (Rio et al., 1987; Henry et al., 1989 Henry et al., , 1991 Foekens et al., 1990 Foekens et al., , 1993 Guerin et al., 1990; Wysocki et al., 1990; Goussard et al., 1991; Schwartz et al., 1991; Klijn et al., 1992; Koerner et al., 1992; Predine et al., 1992; Thor et al., 1992 , Thomson et al., 1993 . In all studies, a positive correlation was observed between pS2 expression and oestrogen receptor status. Moreover, a retrospective study showed that pS2 expression was associated with a good prognosis (Foekens et al., 1990) . More recently, the value of pS2 in predicting the response to hormone therapy in primary (Predine et al., 1992) and advanced breast cancer (Henry et al., 1989 (Henry et al., , 1991 Schwartz et al., 1991; Klijn et al., 1992) has been reported.
We reviewed 319 primary breast tumours for cytosolic pS2 content using the ELSA-pS2 kit (CIS-Bio-industries, Gif-surYvette, France). Both prognostic value (319 patients) and predictive value for the response to adjuvant hormone therapy (84 of the 319 patients) were evaluated.
Materials and methods

Patients
The 319 patients in this study (mean age 55 years; range (Bloom & Richardson, 1957; Scarff & Torloni, 1968 Cytosolic samples For this study, samples were homogenised in 10 mM Tris-HCl buffer, pH 7.4, containing 1.5 mM EDTA, 0.5 mM dithiothreitol and 10% glycerol. Cytosols were aliquoted and stored in liquid nitrogen until use (within 1 month). Cytosolic pS2 was assayed with a commercial immunoradiometric method (ELSA-pS2 kit, CIS, Bio-Industries, Gif-sur-Yvette, France), validated elsewhere (Goussard et al., 1991 small variance in the estimate of the mean for all patients.
We calculated the sum of the squares within groups for each pair of adjacent subgroups, and the combination of subgroups into two large groups that gave the minimum sum of squares was selected. The two groups were analysed by x2. Kaplan-Meier (1958) disease-free (DFS) and overall survival (OS) curves were analysed by the log-rank test. The most significant prognostic factors were identified by a forward selection procedure based on the Cox proportional hazards model (Cox, 1972 (Table I ). In the overall population, pS2 was the first parameter excluded for DFS, while pS2 was the second independent variable for OS after nodal status (Table  Ila) . Overall survival curves defined by the two independent variables (nodal involvement and pS2 status) are shown in Figure 1 . The longest survival time was observed among patients without node involvement and those whose tumours expressed pS2 protein. In contrast, patients with node involvement and pS2-negative primary tumours had an eightfold higher risk of death.
In patients not receiving hormone therapy (Table Ilb) Table I . Months Figure 1 Overall survival curves of the 319 primary breast cancer patients according to the four risk groups defined by the combination of the two significant variables of the Cox model, nodal and pS2 status (P-value of the log-rank test). (Foekens et al., 1993) Predine et al. (1992) . The general tendency for pS2 to be more frequently positive in well-differentiated tumours (Predine et al., 1992; Thor et al., 1992; Foekens et al., 1993) was also confirmed here. No relation was found between pS2 and tumour size or nodal status, as previously reported (Henry et al., 1989; Foekens et al., 1990 Foekens et al., , 1993 Schwartz et al., 1991; Predine et al., 1992; Thor et al., 1992) . In a univariate analysis, pS2 positivity was significantly associated with prolonged disease-free and overall survival, again as already reported (Foekens et al., 1990; Predine et al., 1992; Thor et al., 1992) .
Using Cox multivariate analysis, nodal status was the most important predictive parameter for DFS and OS in these patients with breast cancer. Moreover, in the hormonetreated population, this parameter was the only one that significantly predicted DFS. Although pS2 appears to be poorly predictive of DFS, it was the second independent predictor for the OS, after nodal status. These results for pS2 imply that pS2 protein is not related to the ability of breast tumours to recur and/or form metastases, but rather to the aggressiveness of recurrences and metastases, perhaps through their stage of differentiation, as in the primary tumours. Interestingly, the pS2 value was prognostic both in the overall population and in the hormone-treated patient population, but not in the patients not treated with hormones. Hence, the significance of the pS2 value is related to hormone treatment: patients with tumours containing pS2 respond and survive longer. In other words, the improved survival in the pS2-positive population reflects the response of pS2-containing tumours to endocrine therapy. Such a correlation between pS2 gene expression and a positive response to hormone therapy has already been observed in the treatment of both primary (Predine et al., 1992) and advanced (Henry et al., 1989 (Henry et al., , 1991 Schwartz et al., 1991; Klijn et al., 1992) breast carcinomas. Moreover, pS2 status appears to be more informative than ER and/or PR for selecting patients for hormone treatment.
In conclusion, biological prognostic factors should be viewed not only as parameters that might influence the rate of relapse and death, but also as factors with potential influence on the response to treatment. Overall, the present study confirms that pS2 should be considered as predictive of the response to hormone therapy. The favourable outcome of patients whose tumours express pS2 protein appears to be due both to the favourable effects of endocrine therapy and, to some extent, to an inherently favourable tumour biology.
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